Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The New Political Economy of PharmaceuticalsThe Political Economy of Pharmaceutical Production in Brazil

The New Political Economy of Pharmaceuticals: The Political Economy of Pharmaceutical Production... [Over the last two decades global pharmaceutical production has been shaped by a series of profound political, legal and economic changes.1 On the one hand, the rise of bulk pharmaceutical production in Asia and a wave of mergers and acquisitions throughout the 1990s (Kesic, 2009; Nolan, 2001) has resulted in sector concentration (Abbott and Dukes, 2009; ‘t Hoen, 2009). On the other hand, industry consolidation has been compounded by increasing standardization of intellectual property law. One hundred and fifty-three countries now adhere to the World Trade Organization’s (WTO) Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS). The Agreement’s standard for intellectual property rights (IPR) has been implemented in most developing countries, with significant implications for diffusion of innovation and the range of public health policy options available to local governments. As these global processes have been under way, nation-states have grappled with how to apply new international standards, create fair domestic regulatory frameworks that maintain sufficient levels of competition in the pharmaceutical sector, and ensure access to medicine for their citizens.] http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png

The New Political Economy of PharmaceuticalsThe Political Economy of Pharmaceutical Production in Brazil

Part of the International Political Economy Series Book Series
Editors: Löfgren, Hans; Williams, Owain David
Sweet, Cassandra M.
The New Political Economy of Pharmaceuticals — Nov 6, 2015
Download PDF
18 pages

Loading next page...
 
/lp/springer-journals/the-new-political-economy-of-pharmaceuticals-the-political-economy-of-y8022EKZeg
Publisher
Palgrave Macmillan UK
Copyright
© Palgrave Macmillan, a division of Macmillan Publishers Limited 2013
ISBN
978-1-349-32976-2
Pages
29 –47
DOI
10.1057/9781137315854_2
Publisher site
See Chapter on Publisher Site

Abstract

[Over the last two decades global pharmaceutical production has been shaped by a series of profound political, legal and economic changes.1 On the one hand, the rise of bulk pharmaceutical production in Asia and a wave of mergers and acquisitions throughout the 1990s (Kesic, 2009; Nolan, 2001) has resulted in sector concentration (Abbott and Dukes, 2009; ‘t Hoen, 2009). On the other hand, industry consolidation has been compounded by increasing standardization of intellectual property law. One hundred and fifty-three countries now adhere to the World Trade Organization’s (WTO) Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS). The Agreement’s standard for intellectual property rights (IPR) has been implemented in most developing countries, with significant implications for diffusion of innovation and the range of public health policy options available to local governments. As these global processes have been under way, nation-states have grappled with how to apply new international standards, create fair domestic regulatory frameworks that maintain sufficient levels of competition in the pharmaceutical sector, and ensure access to medicine for their citizens.]

Published: Nov 6, 2015

Keywords: Intellectual Property; World Trade Organization; Intellectual Property Right; Uruguay Round; Outward Foreign Direct Investment

There are no references for this article.